QOP
IMVT icon

Quinn Opportunity Partners’s Immunovant IMVT Stock Holding History

Quinn Opportunity Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$932K Sell
37,500
-23,608
-39% -$611K 0.05% 218
2025
Q4 		$1.55M Hold
61,108
– – 0.07% 190
2025
Q3 		$985K Buy
61,108
+10,000
+20% +$162K 0.07% 186
2025
Q2 		$818K Buy
51,108
+16,008
+46% +$242K 0.07% 205
2025
Q1 		$600K Buy
+35,100
New +$734K 0.04% 256

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Quinn Opportunity Partners's IMVT Position: Q1 2026 in Review

Quinn Opportunity Partners reduced its Immunovant (IMVT) stake by 39% in Q1 2026, selling an estimated $611K and leaving 37,500 shares worth $932K. The position accounts for 0.05% of the portfolio, ranked #218.

Quinn Opportunity Partners first reported a position in IMVT in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.55M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Quinn Opportunity Partners held 37,500 shares of Immunovant worth $932K as of Q1 2026.
  • Quinn Opportunity Partners sold 23,608 Immunovant shares in Q1 2026, an estimated $611K.
  • Immunovant made up 0.05% of Quinn Opportunity Partners's portfolio in Q1 2026, its #218 holding.
  • Quinn Opportunity Partners first reported a position in Immunovant in Q1 2025 and has held it in 5 quarters since.
  • Quinn Opportunity Partners's Immunovant position peaked at $1.55M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.